Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Treating late relapse of paediatric ALL

Share :

5th International ALL Assembly

5 - 7 Nov 2021
Published: 2 Dec 2021
Views: 183
Rating:
Save
Dr Arend von Stackelberg - Charité Universitätsmedizin, Berlin, Germany

Dr Arend von Stackelberg speaks to ecancer about a talk he gave at the recent ALL Assembly 2021 meeting on 'treating late relapse of paediatric ALL'.

He discusses what the current options are for treating patients depending on MRD status and goes into the genetic subgroups which tend to have poorer outcomes.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia ( Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA )
3 Oct 2023
Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment
Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA
Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment ( Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA )
23 Jun 2023
Triplets for newly diagnosed unfit AML patients could be feasible with...
Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain
Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction ( Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain )
15 Jun 2023
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of...
Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL ( Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA )
21 Dec 2022
PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning
Dr Shernan Holtan - University of Minnesota, Minneapolis, USA
PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning ( Dr Shernan Holtan - University of Minnesota, Minneapolis, USA )
15 Dec 2022
An analysis of the worldwide utilisation of haematopoietic stem cell...
Dr Molly Tokaz - Fred Hutchinson Cancer Center, Seattle, USA
An analysis of the worldwide utilisation of haematopoietic stem cell transplantation for acute myeloid leukaemia ( Dr Molly Tokaz - Fred Hutchinson Cancer Center, Seattle, USA )
14 Dec 2022
Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable...
Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA
Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )
12 Dec 2022
Isatuximab + Pd in Difficult-to-Treat Patients with RRMM
Dr Maximilian Merz - Leipzig University, Leipzig, Germany
Isatuximab + Pd in Difficult-to-Treat Patients with RRMM ( Dr Maximilian Merz - Leipzig University, Leipzig, Germany )
11 Jul 2022
Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial
Dr Maximilian Merz - Leipzig University, Leipzig, Germany
Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial ( Dr Maximilian Merz - Leipzig University, Leipzig, Germany )
28 Jun 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation